BioCentury | Oct 27, 2020
Distillery Therapeutics

FAP inhibition for the treatment of osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis The endogenous bone growth factor CLEC11A and other inhibitors of FAP could treat osteoporosis. In cultures of mouse primary bone marrow cells, a tool compound FAP inhibitor reduced osteoclast differentiation. In...
BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...
BioCentury | Jun 13, 2020
Translation in Brief

OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

mAbs against new myeloid checkpoint OSE Immunotherapeutics S.A. (Euronext:OSE) has identified CLEC1A, a carbohydrate-binding protein, as a tumor myeloid checkpoint target, and has generated mAbs that prevent CLEC1A from binding its ligand on tumor cells....
BioCentury | May 29, 2020
Distillery Therapeutics

Blocking platelet activation for acetaminophen-induced liver failure

DISEASE CATEGORY: Hepatic INDICATION: Liver failure Inhibiting signaling by the platelet activating receptor CLEC1B could treat acetaminophen-induced liver failure. mRNA levels of PDPN, the cognate ligand of CLEC1B, were higher in tissue from acetaminophen-injured human...
BioCentury | Jan 31, 2020
Distillery Therapeutics

CLEC14A-positive stem cell transplants for muscle regeneration

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Transplantation with muscle-derived CLEC14A-positive stem cells could regenerate muscle following injury, despite lacking expression of known myogenic regulator PAX7. The myogenic cells were isolated from muscle fiber fragments that underwent...
BioCentury | Jan 30, 2020
Company News

As Spinraza’s sales level off, Biogen presses ahead with aducanumab plans planning a Phase III trial after it revealed last month that the mAb targeting CLEC4C... revenues. The company's shares shed $4.99 to $277.53 on Thursday. Targets: CLEC4C (BDCA2) - C-type lectin domain family 4 member C...
BioCentury | Dec 3, 2019
Clinical News

Biogen plotting next steps in lupus after latest readout

...SLE). Biogen Inc. (NASDAQ:BIIB) said Tuesday that all three doses of BIIB059, a mAb targeting CLEC4C...
...part of Biogen's goal of building a "multi-franchise portfolio" that addresses unmet needs. By targeting CLEC4C...
...$1.69 to $290.70 on Tuesday. Targets; CD40L (CD40LG; CD154) - CD40 ligand; CLEC4C (BDCA2) - C-type lectin domain family 4 member C; Paul...
BioCentury | Jul 24, 2019
Distillery Therapeutics

Simultaneous CLEC5A and TLR2 inhibition for dengue

DISEASE CATEGORY: Infectious disease INDICATION: Dengue fever; viral hemorrhagic fever Simultaneously blocking CLEC5A and TLR2, both pattern recognition receptors linked to microbial infections, could improve survival following dengue virus infection. The inflammatory response to dengue...
BioCentury | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

...adjacencies, including immunology" (see "Baby Steps Beyond Beta Amyloid" ). In immunology, the company has CLEC4C-targeting...
...the next trading day. Targets: CD40L (CD40LG; CD154) - CD 40 ligand; CLEC4C (BDCA2) - C-type lectin domain family 4 member C...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
Items per page:
1 - 10 of 74